dc.contributor.author | Prisinzano, Thomas E. | |
dc.date.accessioned | 2017-04-06T16:10:53Z | |
dc.date.available | 2017-04-06T16:10:53Z | |
dc.date.issued | 2013-05-09 | |
dc.identifier.citation | Prisinzano, T. E. (2013). 2012 David W. Robertson Award for Excellence in Medicinal Chemistry: Neoclerodanes as Atypical Opioid Receptor Ligands. Journal of Medicinal Chemistry, 56(9), 3435–3443. http://doi.org/10.1021/jm400388u | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/23582 | |
dc.description.abstract | The neoclerodane diterpene salvinorin A is the major active component of the hallucinogenic mint plant Salvia divinorum Epling & Játiva (Lamiaceae). Since the finding that salvinorin A exerts its potent psychotropic actions through the activation of opioid receptors, the site of action of morphine and related analogues, there has been much interest in elucidating the underlying mechanisms behind its effects. These effects are particularly remarkable, because (1) salvinorin A is the first reported non-nitrogenous opioid receptor agonist, and (2) its effects are not mediated through the previously investigated targets of psychotomimetics. This perspective outlines our research program, illustrating a new direction to the development of tools to further elucidate the biological mechanisms of drug tolerance and dependence. The information gained from these efforts is expected to facilitate the design of novel agents to treat pain, drug abuse, and other CNS disorders. | en_US |
dc.publisher | American Chemical Society | en_US |
dc.rights | This document is the Accepted Manuscript version of a Published Work that appeared in final form in the Journal of Medicinal Chemistry, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see http://dx.doi.org/10.1021/jm900254k. | en_US |
dc.subject | Opioids | en_US |
dc.subject | Salvinorin A. | en_US |
dc.subject | Salvia divinorum | en_US |
dc.subject | Herkinorin | en_US |
dc.subject | Neoclerodanes | en_US |
dc.title | 2012 David W. Robertson Award for Excellence in Medicinal Chemistry: Neoclerodanes as Atypical Opioid Receptor Ligands | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Prisinzano, Thomas E. | |
kusw.kudepartment | Medicinal Chemistry | en_US |
kusw.oanotes | Per SHERPA/RoMEO 4/6/2017: Author's Pre-print: grey tick subject to Restrictions below, author can archive pre-print (ie pre-refereeing)
Restrictions: Must obtain written permission from Editor
Must not violate ACS ethical GuidelinesAuthor's Post-print: grey tick subject to Restrictions below, author can archive post-print (ie final draft post-refereeing)
Restrictions: If mandated by funding agency or employer/ institution
If mandated to deposit before 12 months, must obtain waiver from Institution/Funding agency or use AuthorChoice
12 months embargoPublisher's Version/PDF: cross author cannot archive publisher's version/PDF
General Conditions: On author's personal website, pre-print servers, institutional website, institutional repositories or subject repositories
Non-Commercial
Must be accompanied by set statement (see policy)
Must link to publisher version
Publisher's version/PDF cannot be used | en_US |
dc.identifier.doi | 10.1021/jm400388u | en_US |
kusw.oaversion | Scholarly/refereed, author accepted manuscript | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.rights.accessrights | openAccess | |